Effect of Tranexamic Acid (TXA) Administered Prior to Shoulder Arthroscopy on Postoperative Pain Medication Usage: A Randomized Controlled Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

165 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-01

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To our knowledge, no studies examining the use of TXA after shoulder arthroscopy in an outpatient setting have been published. This study will evaluate whether TXA reduces pain as measured by opioid consumption and a visual analog scale for pain (VAS) for the first 72 hours after surgery. Secondary outcomes will examine whether patients were satisfied overall with their postoperative pain control, whether the time to first opioid use is increased, and whether the surgeon perceives improved surgical visualization in patients who received TXA. We will also examine the number of times pump pressure was increased during the procedure to improve visualization.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Examining the Effectiveness of a Connective Tissue Matrix Implant in Reducing Post-operative Pain and Narcotic After Outpatient Arthroscopic Shoulder Surgery

NCT04633837

Arthroscopic Shoulder Surgery Pain, Postoperative

TERMINATED NA

Effect of Ibuprofen on Postoperative Opiate Medication Use and Shoulder Functional Outcomes

NCT02588027

Rotator Cuff Tear Arthropathy

COMPLETED NA

Opioid-Free Pain Protocol After Shoulder Arthroplasty

NCT05488847

Shoulder Arthropathy Shoulder Pain

ACTIVE_NOT_RECRUITING PHASE4

Caffeine Study for Pain Control Following Total Joint Replacement

NCT04280263

Pain, Postoperative

UNKNOWN NA

A Randomized Double-Blind Placebo Controlled Trial to Determine the Status of Post Knee Chondroplasty Patients Administered Theramine Versus Placebo in Addition to Post Surgery Analgesics

NCT01534286

Knee Pain Knee Chondroplasty

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We will conduct a double-blind, placebo-controlled randomized clinical trial (RCT) to assess if there is benefit to use of TXA in shoulder arthroscopy. The study will include patients scheduled for rotator cuff repair with or without concomitant procedures. Patients undergoing shoulder arthroscopy for any other reason will be excluded, including isolated labral repair, isolated distal clavicle excision, frozen shoulder, isolated decompression or debridement. Medical exclusion criteria will include allergy or known sensitivity to TXA, known renal disease with previously documented creatinine \>1.5, history of coagulopathy, DVT or PE requiring ongoing anticoagulation, baseline long-acting opioid use, a documented history of COVID-19 infection within 90 days of surgery.

A total of 150 participants will be enrolled and randomized 1:1 to receive either a standard dose of TXA (1000 mg) or an equivalent volume of placebo (normal saline, NS) at the time of surgery. The primary outcome measure will be postoperative opioid consumption as measured by pill count for 72 hours, calculated as morphine equivalent dose (MED). Secondary outcome measures will include subjective measurement of pain as rated on the VAS, time to first opioid use, and patient satisfaction with postoperative pain management at 72 hours. Operative time, surgeon rating of overall visibility during the procedure, and number of times pump pressure was increased during the procedure will also be compared between groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

This Study Will Evaluate Whether TXA Reduces Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients who receive TXA will exhibit less pain

as measured by opioid consumption and VAS for the first 72 hours after surgery

Group Type ACTIVE_COMPARATOR

Tranexamic acid

Intervention Type DRUG

A total of 150 participants will be enrolled and randomized 1:1 to receive either a standard dose of TXA (1000 mg) or an equivalent volume of placebo (normal saline, NS) at the time of surgery. .

Patients who receive placebo will have higher pain

placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tranexamic acid

A total of 150 participants will be enrolled and randomized 1:1 to receive either a standard dose of TXA (1000 mg) or an equivalent volume of placebo (normal saline, NS) at the time of surgery. .

Intervention Type DRUG

placebo

saline

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients scheduled to have shoulder arthroscopy with the PI (KAB)
* shoulder arthroscopy for partial or full thickness rotator cuff tear confirmed on MRI or CT arthrogram preoperatively.
* willing to sign consent to participation and randomization.

Exclusion Criteria

1. Revision procedures
2. Irreparable tears including planned allograft augmentation and superior capsular reconstruction (SCR) procedures
3. Goutallier staging for fatty infiltration of 3 or higher
4. Substantial underlying arthritis (Samuelson and Prieto grade 2 or higher).

1. Allergy, known sensitivity to TXA.
2. Renal insufficiency as defined by serum creatinine \>1.5 prior to surgery.
3. History of coagulopathy, DVT or PE requiring ongoing anticoagulation.
4. Baseline opioid use of long-acting medications including Fentanyl patches, Oxycontin CR, or MS Contin.
5. Documented history of COVID-19 infection within 90 days of surgery.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes